Download MendeleyDual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.
Evers, A., Bossart, M., Pfeiffer-Marek, S., Elvert, R., Schreuder, H., Kurz, M., Stengelin, S., Lorenz, M., Herling, A., Konkar, A., Lukasczyk, U., Pfenninger, A., Lorenz, K., Haack, T., Kadereit, D., Wagner, M.(2018) J Med Chem 61: 5580-5593
- PubMed: 29879354
- DOI: https://doi.org/10.1021/acs.jmedchem.8b00292
- Primary Citation of Related Structures:
6GB1, 6GDZ, 6GE2 - PubMed Abstract:
Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes. We describe novel exendin-4 based dual agonists designed with an activity ratio favoring the GLP-1 versus the glucagon receptor. As result of an iterative optimization procedure that included molecular modeling, structural biological studies (X-ray, NMR), peptide design and synthesis, experimental activity, and solubility profiling, a candidate molecule was identified. Novel SAR points are reported that allowed us to fine-tune the desired receptor activity ratio and increased solubility in the presence of antimicrobial preservatives, findings that can be of general applicability for any peptide discovery project. The peptide was evaluated in chronic in vivo studies in obese diabetic monkeys as translational model for the human situation and demonstrated favorable blood glucose and body weight lowering effects.
Organizational Affiliation:
Sanofi-Aventis Deutschland GmbH , R&D , Industriepark Höchst , D-65926 Frankfurt am Main , Germany.
